Seemingly bad news can sometimes be really good news. I think a recent study for Eli Lilly's (NYSE: LLY) rival to Novo Nordisk's massively successful Ozempic and Wegovy provides a great case in point.

Results from the Surmount-4 clinical trial were published on the Journal of the American Medical Association's website on Dec. 11, 2023. Researchers found that patients who took Lilly's weight loss drug tirzepatide (marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes) regained roughly half of their weight after they stopped taking the drug for one year.

Investors reacted negatively to the news. Lilly's share price fell around 5% before rebounding somewhat. However, my view is that there's more to the story that many investors are missing. Here's why the recent data actually makes Lilly stock an even better buy.

Continue reading

Source Fool.com